id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2015-N-0030-8512,FDA,FDA-2015-N-0030,Extension of the Period Before the Food and Drug Administration Intends to Begin Enforcing the Statutory 5 Percent Limit on Out-of-State Distribution of Compounded Human Drug Products,Rule,Extension of Comment Period,2022-10-21T04:00:00Z,2022,10,2022-10-21T04:00:00Z,,2022-10-21T12:22:13Z,2022-22876,0,0,0900006485442443
FDA-2015-N-0030-8511,FDA,FDA-2015-N-0030,"Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Human Drug Compounding Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act",Notice,30 Day Proposed Information Collection,2022-10-07T04:00:00Z,2022,10,2022-10-07T04:00:00Z,,2022-10-07T17:13:32Z,2022-21841,0,0,09000064853d45d8
FDA-2015-N-0030-8509,FDA,FDA-2015-N-0030,"Agency Information Collection Activities; Proposed Collection; Comment Request; Human Drug Compounding Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act",Notice,60 Day Proposed Information Collection,2022-06-17T04:00:00Z,2022,6,2022-06-17T04:00:00Z,2022-08-17T03:59:59Z,2022-09-19T19:18:53Z,2022-13068,0,0,0900006485178b8f